REPLIMUNE GROUP, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
REPLIMUNE GROUP, INC. (REPL) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $13.00 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-14
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $13.00.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $14.12.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $14.10.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $14.04.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $13.00 10-Q · filed 2026-08-14 |
| 2026-03-31 | $14.12 10-K · filed 2026-06-29 |
| 2025-12-31 | $14.10 10-Q · filed 2026-02-03 |
| 2025-09-30 | $14.04 10-Q · filed 2025-11-06 |
| 2025-06-30 | $14.05 10-Q · filed 2025-08-07 |
| 2025-03-31 | $15.22 10-K · filed 2025-05-22 |
| 2024-12-31 | $15.28 10-Q · filed 2025-02-12 |
| 2024-09-30 | $15.27 10-Q · filed 2024-11-12 |
| 2024-06-30 | $15.37 10-Q · filed 2024-08-08 |
| 2024-03-31 | $16.94 10-K · filed 2024-05-16 |
| 2023-12-31 | $17.23 10-Q · filed 2024-02-08 |
| 2023-09-30 | $17.38 10-Q · filed 2023-11-07 |
| 2023-06-30 | $17.35 10-Q · filed 2023-08-03 |
| 2022-03-31 | $17.24 10-K · filed 2023-05-18 |
| 2018-06-30 | $2.72 10-Q · filed 2018-08-30 |
| 2018-03-31 | $2.72 10-Q · filed 2018-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |